The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KRAS mutations and their prognostic implications in appendiceal cancers.
 
Snigdha Nutalapati
No Relationships to Disclose
 
Negar Sadeghipour
No Relationships to Disclose
 
Joanne Xiu
No Relationships to Disclose
 
Sharon Wu
Employment - Caris Life Sciences
Research Funding - Caris Life Sciences
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Ryan Schmocker
Travel, Accommodations, Expenses - Histosonics
 
Matthew James Oberley
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Travel, Accommodations, Expenses - Caris Life Sciences
 
Anna Reagan
No Relationships to Disclose
 
Hannah McDonald
No Relationships to Disclose
 
Reema Anil Patel
Honoraria - Onc Live
Research Funding - Genentech (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Genentech
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - GlaxoSmithKline
Research Funding - Amgen (Inst); BioMed Valley Discoveries (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Takeda (Inst); Xilio Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Prakash Pandalai
No Relationships to Disclose
 
Joseph Kim
Research Funding - Exelixis (Inst); Ipsen (Inst); Merck (Inst)